+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Leishmaniasis: current status of available drugs and new potential drug targets.

      Asian Pacific journal of tropical medicine

      Aminoquinolines, therapeutic use, Amphotericin B, Antigens, Protozoan, immunology, Antimony Sodium Gluconate, Antiprotozoal Agents, Caspase Inhibitors, Cyclin-Dependent Kinases, antagonists & inhibitors, Drug Discovery, trends, Enzyme Inhibitors, Folic Acid Antagonists, Humans, Leishmaniasis, drug therapy, enzymology, Macrophages, Microbodies, Mitogen-Activated Protein Kinase Kinases, metabolism, Paromomycin, Pentamidine, Phosphorylcholine, analogs & derivatives, Polyamines, Protease Inhibitors, Sterols, biosynthesis, Sulfhydryl Compounds, Topoisomerase Inhibitors

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to pentavalent antimonials, which have been the recommended drugs to treat cutaneous and visceral leishmaniasis, is now widespread in Indian subcontinents. New drug formulations like amphotericin B, its lipid formulations, and miltefosine have shown great efficacy to treat leishmaniasis but their high cost and therapeutic complications limit their usefulness. In addition, irregular and inappropriate uses of these second line drugs in endemic regions like state of Bihar, India threaten resistance development in the parasite. In context to the limited drug options and unavailability of either preventive or prophylactic candidates, there is a pressing need to develop true antileishmanial drugs to reduce the disease burden of this debilitating endemic disease. Notwithstanding significant progress of leishmanial research during last few decades, identification and characterization of novel drugs and drug targets are far from satisfactory. This review will initially describe current drug regimens and later will provide an overview on few important biochemical and enzymatic machineries that could be utilized as putative drug targets for generation of true antileishmanial drugs. Copyright © 2012 Hainan Medical College. Published by Elsevier B.V. All rights reserved.

          Related collections

          Author and article information



          Comment on this article